It's hard to find quality that endures from beginning to end, but that's exactly what you'll get in these action-packed first ...

Four bountiful years in a row for the first time since the late 1990s have meant plentiful supplies.

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported ...

Sophie Raworth explains why younger runners are ditching miles for kilometres – and how the shift is changing motivation, ...

A first-in-human trial found that localized IL-2 delivery via cell implants was well tolerated and demonstrated antitumor ...

BeOne Medicines has entered the BCL-2 arena, securing an FDA green light for Beqalzi that carves out a unique piece of territory ahead of a potential broader clash with market leader Venclexta. The ...

ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H ...

Bank of America Global Healthcare Conference 2026 May 12, 2026 8:01 PM EDTCompany ParticipantsJeffrey Finer - Co-Founder, CEO ...

Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on ...

PC Games often tend to raise questions about the GPU over the CPU. While the GPU gets most of the gamers’ focus, it’s the ...